National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 64804 [2022-23272]
Download as PDF
<![CDATA[
64804
Federal Register / Vol. 87, No. 206 / Wednesday, October 26, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Developing Regulated Therapeutic and
Diagnostic Solutions for Patients Affected by
Opioid and/or Stimulants use Disorders.
Date: November 30, 2022.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5819 ,gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; High
Priority HIV and Substance Use Research.
Date: November 30, 2022.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Trinh T. Tran, Ph.D,.
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5843, trinh.tran@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Pathogenic Mechanisms influencing Blood
Brain Barrier function in HIV and Substance
Use Disorders.
Date: December 6, 2022.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5819, gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
VerDate Sep<11>2014
17:37 Oct 25, 2022
Jkt 259001
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: October 20, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23271 Filed 10–25–22; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Improved Drug
Susceptibility Testing (DST) for Tuberculosis
(R01 Clinical Trial Not Allowed).
Date: November 30–December 1, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases; National Institutes of
Health, 5601 Fishers Lane, Room 3G13,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Brenda Lange-Gustafson,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases; National Institutes of
Health, 5601 Fishers Lane, Room 3G13,
Rockville, MD 20852, 240–669–5047,
bgustafson@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Frm 00051
Fmt 4703
[FR Doc. 2022–23272 Filed 10–25–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2023 Funding
Opportunity
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Dated: October 20, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
Sfmt 4703
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice of intent to award a
single source cooperative agreement to
the Mental Health Association of New
York City, Inc. (DBA Vibrant Emotional
Health).
AGENCY:
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) intends to award $47
million (total costs) for up to one year
to Vibrant Emotional Health for the 988
Suicide and Crisis Lifeline Access
Improvement Project. Funding for this
program is from the Bipartisan Safer
Communities Act, [Pub. L. 117–159,
Division B, Title II]. Under this
cooperative agreement, Vibrant
Emotional Health will expand access to
the local and national Lifeline backup
centers, language services, system
evaluation and data reporting, and
access to specialized care for
populations to be known at higher risk
for suicide by: (1) expanding options for
connection and support for individuals
at higher risk of suicide, which includes
but is not limited to LGBTQI+,
American Indian/Alaska Native, rural
individuals, individuals with mental
illness and substance use disorders,
Black/African-American youth and
older men; (2) expanding current
language access services to include
Spanish chat and text, and videophone
for those deaf and hard of hearing; and
(3) improve access and capacity
utilization of the nationwide backup
system while maximizing state and
territory response.
Funding Opportunity Title: 988
Suicide and Crisis Lifeline Access
Improvement Project.
Assistance Listing Number: 93.243.
Authority: Section 520E–3 of the
Public Health Service Act, as amended.
Justification: Eligibility for this award
is limited to the Mental Health
Association of New York City, Inc. (DBA
Vibrant Emotional Health). Vibrant
Emotional Health is the current Lifeline
SUMMARY:
E:\FR\FM\26OCN1.SGM
26OCN1
]]>Agencies
[Federal Register Volume 87, Number 206 (Wednesday, October 26, 2022)]
[Notices]
[Page 64804]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23272]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Improved Drug Susceptibility
Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed).
Date: November 30-December 1, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases;
National Institutes of Health, 5601 Fishers Lane, Room 3G13,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Brenda Lange-Gustafson, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases;
National Institutes of Health, 5601 Fishers Lane, Room 3G13,
Rockville, MD 20852, 240-669-5047, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 20, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-23272 Filed 10-25-22; 8:45 am]
BILLING CODE 4140-01-P
